Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better

eJHaem

article

Ekaterina Rebmann¹  Mitja Nabergoj²  Bastien Grandjean¹  Paraskevi Stakia³  Alix Stern⁴  Michael Medinger⁵  Stavroula Masouridi-Levrat³  Carole Dantin³  Urs Schanz⁶  Helen Baldomero⁵  Jakob Passweg⁵  Gayathri Nair⁶  Alicia Rovo¹  Yves Chalandon³ 

[1]Department of Hematology, University Hospital of Bern (Inselspital)

[2]Department of Hematology, L’Hôpital Riviera-Chablais

[3]Department of Hematology, Geneva University Hospitals (HUG)

[4]Department of Oncology-Hematology,Hospital of Neuchâtel (RHNE)

[5]Department of Hematology, University Hospital of Basel (USB)

[6]Department of Hematology, University Hospital of Zurich (UZH)

[7]SBST Data Registry Office, Univesiry Hospital of Base

[8]Faculty of Medicine, University of Basel

[9]Faculty of Medicine, University of Geneva

关键词: GVHD;    lymphomas;    stem cell transplantation;   

DOI  :  10.1002/jha2.614

来源: Wiley

【 摘 要 】

Due to relatively high nonrelapse mortality (NRM), allogeneic hematopoietic stem cell transplantation (allo-HSCT) in non-Hodgkin's lymphoma (NHL) remains the ultimate line of treatment but the only curable approach in a setting of relapse/refractory disease. Here, we conducted a retrospective, multicenter, registry-based analysis on patients who underwent allo-HSCT for NHL in Switzerland, over 30-year (1985–2020) period. The study included 301 allo-HSCTs performed for NHL patients in three University Hospitals of Switzerland (Zurich, Basel and Geneva) 09/1985 to 05/2020. We assessed in univariate and multivariable analysis the impact on survivals (overall survival [OS], relapse free survival [RFS], relapse incidence [RI], and non-treatment related mortality [NRM]). The maximum follow-up was 25 years with median follow-up for alive patients of 61 months. The median age at allo-HSCT was 51 years. Three- and -year OS was - 59.5% and 55.4%; 3- and 5-year PFS was 50% and 44%; 3- and 5-year NRM was 21.7% and 23.6%. RI at 3 and 5 years was 27.4% and 34.9%. In conclusion, our analysis of the entire Swiss experience of allo-HSCT in patients with NHL shows promising 5- and possibly 10-year OS and relatively acceptable NRM rates for such population, the majority being not in complete remission (CR) at the time of transplantation.

【 授权许可】

Unknown